Analysts Set ConvaTec Group PLC (LON:CTEC) PT at GBX 320.33

Shares of ConvaTec Group PLC (LON:CTEC) have earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is GBX 320.33.

CTEC has been the topic of several research analyst reports. Berenberg Bank boosted their target price on shares of ConvaTec Group from GBX 330 to GBX 340 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a research note on Friday, November 14th. UBS Group restated a “buy” rating and issued a GBX 375 target price on shares of ConvaTec Group in a research note on Friday, November 7th. Finally, Peel Hunt reiterated an “add” rating and set a GBX 270 price target on shares of ConvaTec Group in a research note on Thursday, November 13th.

ConvaTec Group Price Performance

Shares of LON CTEC opened at GBX 228.80 on Friday. ConvaTec Group has a fifty-two week low of GBX 209.40 and a fifty-two week high of GBX 311.20. The company has a debt-to-equity ratio of 85.32, a quick ratio of 0.96 and a current ratio of 2.26. The company has a market cap of £4.46 billion, a PE ratio of 21.58, a P/E/G ratio of 0.93 and a beta of 0.64. The business has a 50-day simple moving average of GBX 234.24 and a two-hundred day simple moving average of GBX 235.51.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.